Literature DB >> 1542794

The IL-6 signal transducer, gp130: an oncostatin M receptor and affinity converter for the LIF receptor.

D P Gearing1, M R Comeau, D J Friend, S D Gimpel, C J Thut, J McGourty, K K Brasher, J A King, S Gillis, B Mosley.   

Abstract

Leukemia inhibitory factor (LIF) and interleukin-6 (IL-6) are multifunctional cytokines with many similar activities. LIF is structurally and functionally related to another cytokine, Oncostatin M (OSM), that binds to the high-affinity LIF receptor but not to the low-affinity LIF receptor. A complementary DNA was isolated that encodes the high-affinity converting subunit of the LIF receptor. The converter conferred high-affinity binding of both LIF and OSM when expressed with the low-affinity LIF receptor and is identical to the signal transducing subunit of the IL-6 receptor, gp130. The gp130 subunit alone confers low-affinity binding of OSM when expressed in COS-7 cells. This receptor system resembles the high-affinity receptors for granulocyte-macrophage colony-stimulating factor, IL-3, and IL-5, which share a common subunit.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1542794     DOI: 10.1126/science.1542794

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  178 in total

1.  Evidence for the formation of a heterotrimeric complex of leukaemia inhibitory factor with its receptor subunits in solution.

Authors:  J G Zhang; C M Owczarek; L D Ward; G J Howlett; L J Fabri; B A Roberts; N A Nicola
Journal:  Biochem J       Date:  1997-08-01       Impact factor: 3.857

Review 2.  Cytokine receptors: structure and signal transduction.

Authors:  B M Foxwell; K Barrett; M Feldmann
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

3.  Functional inhibition of hematopoietic and neurotrophic cytokines by blocking the interleukin 6 signal transducer gp130.

Authors:  T Taga; M Narazaki; K Yasukawa; T Saito; D Miki; M Hamaguchi; S Davis; M Shoyab; G D Yancopoulos; T Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

4.  Regulation of neurokine receptor signaling and trafficking.

Authors:  Neil M Nathanson
Journal:  Neurochem Int       Date:  2012-01-25       Impact factor: 3.921

5.  Fetal liver development requires a paracrine action of oncostatin M through the gp130 signal transducer.

Authors:  A Kamiya; T Kinoshita; Y Ito; T Matsui; Y Morikawa; E Senba; K Nakashima; T Taga; K Yoshida; T Kishimoto; A Miyajima
Journal:  EMBO J       Date:  1999-04-15       Impact factor: 11.598

Review 6.  Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway.

Authors:  P C Heinrich; I Behrmann; G Müller-Newen; F Schaper; L Graeve
Journal:  Biochem J       Date:  1998-09-01       Impact factor: 3.857

7.  Oncostatin-M stimulates tyrosine protein phosphorylation in parallel with the activation of p42MAPK/ERK-2 in Kaposi's cells. Evidence that this pathway is important in Kaposi cell growth.

Authors:  M C Amaral; S Miles; G Kumar; A E Nel
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

8.  Distinct regions of the human granulocyte-colony-stimulating factor receptor cytoplasmic domain are required for proliferation and gene induction.

Authors:  S F Ziegler; T A Bird; K K Morella; B Mosley; D P Gearing; H Baumann
Journal:  Mol Cell Biol       Date:  1993-04       Impact factor: 4.272

Review 9.  Role of signal transducer and activator of transcription 3 in neuronal survival and regeneration.

Authors:  Suzan Dziennis; Nabil J Alkayed
Journal:  Rev Neurosci       Date:  2008       Impact factor: 4.353

10.  Functional coupling of the src-family protein tyrosine kinases p59fyn and p53/56lyn with the interleukin 2 receptor: implications for redundancy and pleiotropism in cytokine signal transduction.

Authors:  N Kobayashi; T Kono; M Hatakeyama; Y Minami; T Miyazaki; R M Perlmutter; T Taniguchi
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.